Results from subgroup analyses
| Examination of effect modification within clinically relevant subgroups∗ . | Users . | Nonusers . | HR (95% CI) for VTE . | P for interaction for VTE∗ . | HR (95% CI) for bleeding . | P for interaction for bleeding∗ . |
|---|---|---|---|---|---|---|
| Age, y | ||||||
| <65 | 19 205 | 19 205 | 0.69 (0.40-1.19) | .63 | 1.06 (0.84-1.34) | .09 |
| ≥65 | 8442 | 8442 | 1.38 (1.02-1.87) | 1.38 (1.03-1.90) | ||
| Sex | .21 | .51 | ||||
| Male | 11 528 | 11 528 | 1.06 (0.63-1.79) | 1.13 (0.86-1.49) | ||
| Female | 16 322 | 16 322 | 0.54 (0.29-0.99) | 1.18 (0.92-1.53) | ||
| Cancer | .11 | .68 | ||||
| Yes | 1861 | 1861 | 1.14 (0.40-3.26) | 1.18 (0.66-2.11) | ||
| No | 25 947 | 25 947 | 0.76 (0.50-1.16) | 1.03 (0.84-1.25) | ||
| IBD type | .06 | .02 | ||||
| UC | 11 361 | 11 361 | 0.65 (0.37-1.15) | 0.99 (0.76-1.29) | ||
| CD | 17 377 | 17 377 | 0.46 (0.22-0.94) | 1.12 (0.89-1.45) | ||
| Heart failure | .97 | .84 | ||||
| Yes | 1885 | 1885 | 0.53 (0.13-2.12) | 1.58 (0.93-2.71) | ||
| No | 25 966 | 25 966 | 0.61 (0.39-0.95) | 1.03 (0.84-1.26) | ||
| IBD flares | ||||||
| Yes | 5093 | 5093 | 0.70 (0.26-1.88) | .94 | 1.02 (0.70-1.47) | .02 |
| No | 22 985 | 22 985 | 0.55 (0.33-0.92) | 1.13 (0.91-1.41) |
| Examination of effect modification within clinically relevant subgroups∗ . | Users . | Nonusers . | HR (95% CI) for VTE . | P for interaction for VTE∗ . | HR (95% CI) for bleeding . | P for interaction for bleeding∗ . |
|---|---|---|---|---|---|---|
| Age, y | ||||||
| <65 | 19 205 | 19 205 | 0.69 (0.40-1.19) | .63 | 1.06 (0.84-1.34) | .09 |
| ≥65 | 8442 | 8442 | 1.38 (1.02-1.87) | 1.38 (1.03-1.90) | ||
| Sex | .21 | .51 | ||||
| Male | 11 528 | 11 528 | 1.06 (0.63-1.79) | 1.13 (0.86-1.49) | ||
| Female | 16 322 | 16 322 | 0.54 (0.29-0.99) | 1.18 (0.92-1.53) | ||
| Cancer | .11 | .68 | ||||
| Yes | 1861 | 1861 | 1.14 (0.40-3.26) | 1.18 (0.66-2.11) | ||
| No | 25 947 | 25 947 | 0.76 (0.50-1.16) | 1.03 (0.84-1.25) | ||
| IBD type | .06 | .02 | ||||
| UC | 11 361 | 11 361 | 0.65 (0.37-1.15) | 0.99 (0.76-1.29) | ||
| CD | 17 377 | 17 377 | 0.46 (0.22-0.94) | 1.12 (0.89-1.45) | ||
| Heart failure | .97 | .84 | ||||
| Yes | 1885 | 1885 | 0.53 (0.13-2.12) | 1.58 (0.93-2.71) | ||
| No | 25 966 | 25 966 | 0.61 (0.39-0.95) | 1.03 (0.84-1.26) | ||
| IBD flares | ||||||
| Yes | 5093 | 5093 | 0.70 (0.26-1.88) | .94 | 1.02 (0.70-1.47) | .02 |
| No | 22 985 | 22 985 | 0.55 (0.33-0.92) | 1.13 (0.91-1.41) |
We used Bonferroni adjustment to account for multiple testing. Results were considered statistically significant if the corresponding P value was ≤ α (ie, .05) / n, in which n = total number of subgroup analyses.